Sociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study

ERS International Congress 2022: highlights from the Respiratory Clinical Care and Physiology Assembly

“…According to Global Initiative for Asthma (GINA) guidelines, this treatment plan is no longer recommended without the concomitant use of inhaled corticosteroids [6]. Through a univariate post-hoc analysis, Al Zaabi et al (Abu Dhabi) showed that a significantly higher percentage of patients prescribed ≥3 vs 1-2 SABA canisters/year with uncontrolled asthma (35.6% vs 21.2%), reported one (24.6% vs 21.0%), two (14.2% vs 9.3%) or ≥3 severe asthma exacerbations (18.0% vs 11.0%) [7]. Therefore, it is important for clinicians to identify this group of patients who are at risk of SABA overuse in order to ameliorate asthma outcomes globally.…”

“…Through a univariate post hoc analysis, A lzaabi et al . [ 7 ] (Abu Dhabi, United Arab Emirates) showed that a significantly higher percentage of patients prescribed ≥3 versus 1–2 SABA canisters per year had uncontrolled asthma (35.6% versus 21.2%), and reported one (24.6% versus 21.0%), two (14.2% versus 9.3%) or ≥3 severe asthma exacerbations (18.0% versus 11.0%). Therefore, it is important for clinicians to identify this group of patients who are at risk of SABA overuse, in order to ameliorate asthma outcomes globally.…”